PR Newswire·Dec 4, 2025, 10:55 AM ET

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Faruqi & Faruqi, LLP is investigating potential securities law violations by Skye Biosciences, Inc. (NYSE: SKYE) regarding false or misleading statements about its drug nimacimab.
The firm reminds investors of the January 16, 2026 deadline to seek the role of lead plaintiff in the federal class action lawsuit.
Investors who purchased Skye securities between November 4, 2024, and October 3, 2025, are encouraged to contact partner James (Josh) Wilson to discuss legal rights.
The complaint alleges the company overstated nimacimab's clinical, regulatory, and commercial prospects while failing to disclose its lower-than-expected effectiveness.
Skye's stock price fell 60% (dropping $2.85 per share to $1.90) on October 6, 2025, following a press release stating the drug failed to achieve its primary weight loss endpoint in a Phase 2a study.
The lawsuit cites specific issues including lower-than-expected drug exposure in the nimacimab monotherapy arm which may require higher dosing.
Any class member may move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in potential recovery.
The firm is also seeking information from whistleblowers, former employees, shareholders, and others regarding Skye's conduct.